Huntington Bancshares Incorporated Reports 2026 Second-Quarter Earnings

Huntington Bancshares reported Q2 EPS of $0.33, up $0.08 QoQ and +39% net income to $727M, with adjusted EPS of $0.39 excluding notable acquisition-related items. Net interest income rose $161M (+9%) QoQ and $585M (+40%) YoY, while noninterest income increased $103M (+15%) QoQ and $314M (+67%) YoY, alongside 9% QoQ loan growth to $189.3B (including Cadence/Veritex). Credit metrics remained broadly contained (net charge-offs 0.25% of average loans; NPA ratio 0.85% +13bps QoQ), CET1 was 10.0%, and the company repurchased $159M of shares in the quarter. Management also highlighted successful Cadence systems conversion in mid-June and expects full earnings power of integrations by 4Q.

Analysis

The market should read this as a clean transition from integration story to monetization story. The key mechanism is that the bank is now less about absorbing deal noise and more about proving it can convert balance-sheet scale into durable fee/NII leverage; that usually supports a higher multiple if deposit retention and cross-sell hold for 2-3 quarters after conversion. In the near term, HBAN likely screens well versus the regional-bank group because the quarter reduces uncertainty around execution and keeps buybacks alive, but the stock still depends on whether the next print shows true organic growth rather than acquisition lift.

Second-order effects matter more than the headline beat: if HBAN is successfully extracting synergies in acquired footprints, competitors in Ohio/Midwest/Carolinas may face more aggressive pricing on commercial deposits and middle-market lending. That pressures peers with weaker core deposit franchises and higher funding costs, especially smaller regionals that cannot offset spread compression with the same fee base. The flip side is that the balance-sheet cushion is no longer as wide as investors may want for a bank still digesting multiple deals; if credit normalizes, capital return could slow just as the market starts to extrapolate the synergy run-rate.

The contrarian view is that consensus may be overpaying for a quarter that is still partially acquisition arithmetic. The falsifier is simple: if next quarter does not show stable CET1, continued buybacks, and incremental organic loan growth after the integration dust settles, the re-rating should fade. Over 6-18 months, the real test is whether the combined franchise can sustain above-peer ROTCE without leaning on M&A, because that determines whether HBAN deserves a premium to KRE rather than just a temporary post-print bounce.

Key Decisions for Investors

• Long HBAN vs short KRE for 1-3 months: express a relative-quality thesis on integration completion and capital return; target 5-8% outperformance if deposit and NII trends hold, stop if HBAN guidance implies slower buybacks or CET1 slips materially below 9.5%.
• Add HBAN on any post-earnings pullback over the next 3-5 trading days: the catalyst path is the next quarterly update showing whether synergy capture is recurring; risk/reward improves if the stock gives back the initial pop while management keeps buybacks active.
• Use NBHC as a regional-bank quality hedge if you want less event risk: if the market rewards HBAN’s scale execution, smaller peers with weaker fee mix should underperform on funding-cost fears.
• Watch for a short opportunity in the regional bank basket if HBAN peers do not re-rate: if other regionals fail to match HBAN’s deposit and fee momentum in the next 1-2 earnings cycles, long HBAN / short KRE should continue to work.
• Set a thesis-failure alert on HBAN if organic loan growth stalls or credit metrics worsen into the next quarter: a rise in charge-offs/NPA or a CET1 drag below the 10% area would cap multiple expansion.